Chiesi Limited - rizultati

chiesi australia pty ltd - nabiximols, quantity: 80 mg/ml - spray, solution - excipient ingredients: propylene glycol; peppermint oil; ethanol absolute - sativex is indicated as treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

cleviprex

chiesi new zealand limited t/a emerge health - clevidipine 0.5 mg/ml (as clevidipine butyrate); - emulsion for injection - 0.5 mg/ml - active: clevidipine 0.5 mg/ml (as clevidipine butyrate) excipient: egg lecithin glycerol sodium hydroxide soya oil water for injection

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

curosurf

chiesi new zealand limited t/a emerge health - poractant alfa 80 mg/ml - suspension for injection - 80 mg/ml - active: poractant alfa 80 mg/ml excipient: sodium bicarbonate sodium chloride - ·treatment of respiratory distress syndrome (rds) in pre-term babies. ·prophylactic use in premature infants at risk for rds.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

asacol mesalazine 800 mg enteric coated tablets blister pack

chiesi australia pty ltd - mesalazine, quantity: 800 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; purified talc; povidone; methacrylic acid copolymer; triethyl citrate; iron oxide yellow; iron oxide red; macrogol 6000 - for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.